Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Yeh, Chau Ting ^b   Chen, Hui Chin ^b   Sung, Chang Mu ^a   Hsu, Cheng Lung ^a   Lin, Chen Chun ^a   Pan, Kuang Tse ^a   Tseng, Jeng Hwei ^a   Hung, Chien Fu ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HEPATITIS C ANTIBODY; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BLEEDING DISORDER; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; FEMALE; FLAPPING TREMOR; HEPATIC ENCEPHALOPATHY; HUMAN; INFECTION; JAUNDICE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PORTAL VEIN THROMBOSIS; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; AGED; CARCINOMA; CLINICAL PROTOCOL; COMPARATIVE STUDY; DISEASE COURSE; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; CLINICAL PROTOCOLS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOXANTRONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79953166120     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-117     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-6. 10.1002/ijc.1440, 11668491.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-38. 10.1016/j.jhep.2006.05.013, 16879891.
3. Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S, Sugimachi K, Kanematsu T, Ohryohji F, Ishibashi H. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int J Cancer 1992, 51:509-14. 10.1002/ijc.2910510402, 1318264.
4. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005, 25:143-54. 10.1055/s-2005-871194, 15918143.
5. Kaido T, Uemoto S. Recent evidence in the treatment of small hepatocellular carcinoma. Hepatogastroenterology 2008, 55:1460-2.
6. Lai MW, Huang SF, Lin SM, Chen TC, Lin CY, Yeh CN, Yeh TS, Chen MF, Yeh CT. Expression of the HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical resection. Hepatol Res 2009, 39:164-76. 10.1111/j.1872-034X.2008.00413.x, 19208037.
7. Biselli M, Andreone P, Gramenzi A, Trevisani F, Cursaro C, Rossi C, Ricca Rosellini S, Cammà C, Lorenzini S, Stefanini GF, Gasbarrini G, Bernardi M. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol 2005, 3:918-25. 10.1016/S1542-3565(05)00425-8, 16234031.
8. Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, Lee PC, Chang FY, Lee SD. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther 2006, 23:129-35. 10.1111/j.1365-2036.2006.02704.x, 16393290.
9. Chok KS, Ng KK, Poon RT, Lam CM, Yuen J, Tso WK, Fan ST. Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg 2006, 141:1231-6. 10.1001/archsurg.141.12.1231, 17178966.
10. Haider Z, ul Haq T, Munir K, Usman MU, Azeemuddin M. Median survival time of patients after transcatheter chemo-embolization for hepatocellular carcinoma. J Coll Physicians Surg Pak 2006, 16:265-9.
11. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005, 92:1862-8. 10.1038/sj.bjc.6602590, 2361778, 15870713.
12. O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003, 90:325-31.
13. Lladó L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, Torras J, Fabregat J, Guardiola J, Jaurrieta E. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000, 88:50-7.
14. Farinati F, De Maria N, Marafin C, Herszènyi L, Del Prato S, Rinaldi M, Perini L, Cardin R, Naccarato R. Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci 1996, 41:2332-9. 10.1007/BF02100123, 9011438.
15. Stefanini GF, Amorati P, Biselli M, Mucci F, Celi A, Arienti V, Roversi R, Rossi C, Re G, Gasbarrini G. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995, 75:2427-34. 10.1002/1097-0142(19950515)75:10<2427::AID-CNCR2820751007>3.0.CO;2-J, 7736385.
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, . SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-90. 10.1056/NEJMoa0708857, 18650514, SHARP Investigators Study Group.
17. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
18. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?. Oncologist 2006, 11:790-800. 10.1634/theoncologist.11-7-790, 16880238.
19. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005, 103:756-62. 10.1002/cncr.20841, 15637692.
20. Yang TS, Chang HK, Chen JS, Lin YC, Liaw CT, Chang WC. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. J Gastroenterol 2004, 39:362-369. 10.1007/s00535-003-1303-8, 15168248.
21. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer 2008, 44:1000-6. 10.1016/j.ejca.2008.02.018, 18337087.
22. Stempak D, Seely D, Baruchel S. Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Invest 2006, 24:432-43. 10.1080/07357900600705599, 16777697.
23. Chen CH, Chang TT, Cheng KS, Su WW, Yang SS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int 2006, 26:766-73. 10.1111/j.1478-3231.2006.01309.x, 16911457.
24. Tanaka Y, Esumi M, Shikata T. Frequent integration of hepatitis B virus DNA in noncancerous liver tissue from hepatocellular carcinoma patients. J Med Virol 1988, 26:7-14. 10.1002/jmv.1890260103, 2846771.